tradingkey.logo

CVRx Inc

CVRX
7.820USD
-0.210-2.62%
收盤 12/22, 16:00美東報價延遲15分鐘
204.83M總市值
虧損本益比TTM

CVRx Inc

7.820
-0.210-2.62%

關於 CVRx Inc 公司

CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.

CVRx Inc簡介

公司代碼CVRX
公司名稱CVRx Inc
上市日期Jun 30, 2021
CEOHykes (Kevin)
員工數量206
證券類型Ordinary Share
年結日Jun 30
公司地址9201 West Broadway Avenue
城市MINNEAPOLIS
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編55445
電話17634162850
網址https://www.cvrx.com/
公司代碼CVRX
上市日期Jun 30, 2021
CEOHykes (Kevin)

CVRx Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Kevin Hykes
Mr. Kevin Hykes
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
35.00K
+16.67%
Mr. Joseph P. (Joe) Slattery, CPA
Mr. Joseph P. (Joe) Slattery, CPA
Lead Independent Director
Lead Independent Director
30.64K
--
Mr. Paul Verrastro
Mr. Paul Verrastro
Chief Marketing and Strategy Officer
Chief Marketing and Strategy Officer
16.84K
+1916.17%
Mr. Brent Binkowski
Mr. Brent Binkowski
Chief Operating Officer
Chief Operating Officer
16.60K
--
Mr. Jared Oasheim
Mr. Jared Oasheim
Chief Financial Officer
Chief Financial Officer
15.45K
-58.75%
Ms. Martha Shadan
Ms. Martha Shadan
Independent Director
Independent Director
--
--
Dr. Mudit K. Jain, Ph.D.
Dr. Mudit K. Jain, Ph.D.
Independent Director
Independent Director
--
--
Dr. Philip B. Adamson
Dr. Philip B. Adamson
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Kevin Ballinger
Mr. Kevin Ballinger
Independent Director
Independent Director
--
--
Mr. Kirk Nielsen
Mr. Kirk Nielsen
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Kevin Hykes
Mr. Kevin Hykes
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
35.00K
+16.67%
Mr. Joseph P. (Joe) Slattery, CPA
Mr. Joseph P. (Joe) Slattery, CPA
Lead Independent Director
Lead Independent Director
30.64K
--
Mr. Paul Verrastro
Mr. Paul Verrastro
Chief Marketing and Strategy Officer
Chief Marketing and Strategy Officer
16.84K
+1916.17%
Mr. Brent Binkowski
Mr. Brent Binkowski
Chief Operating Officer
Chief Operating Officer
16.60K
--
Mr. Jared Oasheim
Mr. Jared Oasheim
Chief Financial Officer
Chief Financial Officer
15.45K
-58.75%
Ms. Martha Shadan
Ms. Martha Shadan
Independent Director
Independent Director
--
--

收入明細

單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
由於公司未披露,未能獲取相關數據
地區USD
名稱
營收
佔比
US
12.24M
90.09%
Others
1.35M
9.91%
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 11月16日 週日
更新時間: 11月16日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Johnson & Johnson Innovation-JJDC, Inc.
15.42%
New Enterprise Associates (NEA)
7.73%
Vensana Capital Management LLC
6.53%
Gilde Equity Management Benelux B.V.
4.69%
The Vanguard Group, Inc.
4.16%
其他
61.47%
持股股東
持股股東
佔比
Johnson & Johnson Innovation-JJDC, Inc.
15.42%
New Enterprise Associates (NEA)
7.73%
Vensana Capital Management LLC
6.53%
Gilde Equity Management Benelux B.V.
4.69%
The Vanguard Group, Inc.
4.16%
其他
61.47%
股東類型
持股股東
佔比
Venture Capital
29.68%
Investment Advisor
11.15%
Hedge Fund
9.28%
Investment Advisor/Hedge Fund
5.96%
Private Equity
4.69%
Individual Investor
4.33%
Research Firm
3.62%
Pension Fund
0.42%
Bank and Trust
0.14%
其他
30.72%

機構持股

更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
228
17.05M
80.90%
-52.59K
2025Q3
232
17.10M
82.20%
-620.32K
2025Q2
227
17.72M
82.14%
-1.50M
2025Q1
219
19.22M
81.40%
-1.99M
2024Q4
217
18.52M
88.19%
+738.46K
2024Q3
205
17.48M
85.56%
+1.01M
2024Q2
202
16.95M
94.67%
-325.79K
2024Q1
200
17.25M
89.54%
-2.08M
2023Q4
194
16.01M
92.75%
+1.64M
2023Q3
187
14.37M
98.58%
+302.86K
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Johnson & Johnson Innovation-JJDC, Inc.
4.10M
15.69%
--
--
Jun 30, 2025
New Enterprise Associates (NEA)
2.03M
7.75%
--
--
Jun 30, 2025
Vensana Capital Management LLC
1.71M
6.54%
--
--
Dec 31, 2024
Gilde Equity Management Benelux B.V.
1.23M
4.7%
-136.72K
-10.01%
Feb 04, 2025
The Vanguard Group, Inc.
1.08M
4.12%
+70.56K
+7.01%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
949.05K
3.63%
+27.13K
+2.94%
Jun 30, 2025
Jain (Mudit Kumar)
938.43K
3.59%
+1.65K
+0.18%
May 13, 2025
Balyasny Asset Management LP
674.68K
2.58%
+267.06K
+65.52%
Jun 30, 2025
Parkman Healthcare Partners LLC
789.10K
3.02%
-440.42K
-35.82%
Jun 30, 2025
Morgan Stanley & Co. LLC
347.67K
1.33%
+158.18K
+83.48%
Jun 30, 2025
查看更多

持股ETF

更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.03%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
JPMorgan Fundamental Data Science Small Core ETF
0%
iShares Russell 2000 Value ETF
0%
Avantis US Small Cap Equity ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
查看更多
iShares Micro-Cap ETF
佔比0.03%
Proshares Ultra Russell 2000
佔比0.01%
ProShares UltraPro Russell2000
佔比0.01%
iShares Russell 2000 Growth ETF
佔比0.01%
Global X Russell 2000 ETF
佔比0.01%
ProShares Hedge Replication ETF
佔比0.01%
JPMorgan Fundamental Data Science Small Core ETF
佔比0%
iShares Russell 2000 Value ETF
佔比0%
Avantis US Small Cap Equity ETF
佔比0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據

常見問題

CVRx Inc的前五大股東是誰?

CVRx Inc的前五大股東如下:
Johnson & Johnson Innovation-JJDC, Inc.
持有股份:4.10M
佔總股份比例:15.69%。
New Enterprise Associates (NEA)
持有股份:2.03M
佔總股份比例:7.75%。
Vensana Capital Management LLC
持有股份:1.71M
佔總股份比例:6.54%。
Gilde Equity Management Benelux B.V.
持有股份:1.23M
佔總股份比例:4.70%。
The Vanguard Group, Inc.
持有股份:1.08M
佔總股份比例:4.12%。

CVRx Inc的前三大股東類型是什麼?

CVRx Inc 的前三大股東類型分別是:
Johnson & Johnson Innovation-JJDC, Inc.
New Enterprise Associates (NEA)
Vensana Capital Management LLC

有多少機構持有CVRx Inc(CVRX)的股份?

截至2025Q4,共有228家機構持有CVRx Inc的股份,合計持有的股份價值約為17.05M,占公司總股份的80.90% 。與2025Q3相比,機構持股有所增加,增幅為-1.30%。

哪個業務部門對CVRx Inc的收入貢獻最大?

在FY2025Q2,--業務部門對CVRx Inc的收入貢獻最大,創收--,占總收入的--% 。
KeyAI